uniQure (NASDAQ:QURE) Director Sells $53,930.58 in Stock

uniQure N.V. (NASDAQ:QURE) Director Leonard Post sold 1,993 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director directly owned 35,494 shares of the company’s stock, valued at $960,467.64. The trade was a 5.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

uniQure Stock Up 2.8%

QURE traded up $0.75 on Friday, hitting $27.57. 835,627 shares of the company were exchanged, compared to its average volume of 2,601,234. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $22.31 and a two-hundred day moving average price of $21.76.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. On average, equities analysts predict that uniQure N.V. will post -3.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

QURE has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Barclays lowered their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Monday, March 23rd. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. Finally, TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Torren Management LLC acquired a new stake in shares of uniQure in the 4th quarter valued at about $28,000. Jones Financial Companies Lllp boosted its position in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc acquired a new stake in shares of uniQure in the 4th quarter valued at about $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the 4th quarter valued at about $48,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the 3rd quarter valued at about $50,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.